Ready to play
Ready to play
Johnson & Johnson plans a $55 billion investment in the U.S., creating high-skilled jobs and strengthening domestic manufacturing, driven by favorable tax policies and a strong investment climate. The company aims to produce all its medicines and medical technologies in the U.S., including a new billion-dollar vision manufacturing facility. Focused on innovation, J&J is advancing medicines like Icotyde and developing a robotic surgical system, targeting sustained growth and double-digit revenue increases by the end of the decade.
Notice: This Is an AI-Generated Summary
Comments (0)